Nectar Lifesciences profitability ratios
Per cent unless marked ×
| Tap a line for its trend | Last 12Mto Jun 2026 | FY26Mar 2026 | FY25Mar 2025 | FY24Mar 2024 | FY23Mar 2023 | FY22 and earlierAlpha Plus |
|---|
Returns | FY22 and earlierEvery year the company has filed comes with Alpha Plus. | |||||
|---|---|---|---|---|---|---|
| −38.1% | −38.1% | −11.2% | 0.5% | −2.3% | ||
| −22.0% | −22.0% | −5.4% | 0.2% | −1.1% | ||
| −7.5% | −7.5% | −7.9% | 7.3% | −0.4% | ||
| −6.3% | −7.0% | −4.1% | 2.2% | −0.2% | ||
Margins | ||||||
| −1,779.9% | — | −1.6% | 9.1% | 3.5% | ||
| — | — | −5.3% | 5.5% | −0.3% | ||
| — | −1.7% | 1,443.2% | 60.6% | — | ||
| −507.9% | — | −9.7% | 1.1% | −2.8% | ||
| −4,890.3% | — | −6.8% | 0.3% | −1.6% | ||
| — | — | — | 0.3% | −1.6% | ||
| — | — | 7.5% | 11.6% | 6.8% | ||
Additional | ||||||
| 156.4% | 34.7% | 29.6% | 72.7% | 43.0% | ||
| −38.1% | −38.1% | −11.2% | 0.5% | −2.3% | ||
From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.